Viridian Therapeutics Competitors

Viridian Therapeutics (NASDAQ:VRDN) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares Viridian Therapeutics and Longboard Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and recommmendations for Viridian Therapeutics and Longboard Pharmaceuticals, as reported by MarketBeat.

Viridian Therapeutics presently has a consensus price target of $34.00, indicating a potential upside of 130.35%. Longboard Pharmaceuticals has a consensus price target of $32.75, indicating a potential upside of 181.60%. Given Longboard Pharmaceuticals' higher possible upside, analysts clearly believe Longboard Pharmaceuticals is more favorable than Viridian Therapeutics.

Earnings & Valuation

This table compares Viridian Therapeutics and Longboard Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Summary

Longboard Pharmaceuticals beats Viridian Therapeutics on 2 of the 2 factors compared between the two stocks.

ImmunoPrecise Antibodies (NASDAQ:IPA) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Profitability

This table compares ImmunoPrecise Antibodies and Viridian Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares ImmunoPrecise Antibodies and Viridian Therapeutics' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of recent ratings and price targets for ImmunoPrecise Antibodies and Viridian Therapeutics, as provided by MarketBeat.com.

Viridian Therapeutics has a consensus target price of $34.00, suggesting a potential upside of 130.35%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than ImmunoPrecise Antibodies.

Summary

Viridian Therapeutics beats ImmunoPrecise Antibodies on 3 of the 3 factors compared between the two stocks.

Gain Therapeutics (NASDAQ:GANX) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Valuation and Earnings

This table compares Gain Therapeutics and Viridian Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Gain Therapeutics and Viridian Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Gain Therapeutics and Viridian Therapeutics, as reported by MarketBeat.

Gain Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 106.90%. Viridian Therapeutics has a consensus target price of $34.00, indicating a potential upside of 130.35%. Given Viridian Therapeutics' higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than Gain Therapeutics.

Summary

Viridian Therapeutics beats Gain Therapeutics on 1 of the 1 factors compared between the two stocks.

Viridian Therapeutics (NASDAQ:VRDN) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Viridian Therapeutics and Annovis Bio's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Viridian Therapeutics and Annovis Bio's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Viridian Therapeutics and Annovis Bio, as reported by MarketBeat.com.

Viridian Therapeutics presently has a consensus price target of $34.00, suggesting a potential upside of 130.35%. Given Viridian Therapeutics' higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Annovis Bio.

Summary

Viridian Therapeutics beats Annovis Bio on 2 of the 2 factors compared between the two stocks.

Viridian Therapeutics (NASDAQ:VRDN) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.

Profitability

This table compares Viridian Therapeutics and Vincerx Pharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for Viridian Therapeutics and Vincerx Pharma, as reported by MarketBeat.

Viridian Therapeutics presently has a consensus target price of $34.00, suggesting a potential upside of 130.35%. Given Viridian Therapeutics' higher possible upside, equities research analysts clearly believe Viridian Therapeutics is more favorable than Vincerx Pharma.

Earnings and Valuation

This table compares Viridian Therapeutics and Vincerx Pharma's revenue, earnings per share and valuation.

Summary

Viridian Therapeutics beats Vincerx Pharma on 2 of the 2 factors compared between the two stocks.

Viridian Therapeutics (NASDAQ:VRDN) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Valuation and Earnings

This table compares Viridian Therapeutics and Evaxion Biotech A/S's gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Viridian Therapeutics and Evaxion Biotech A/S, as provided by MarketBeat.

Viridian Therapeutics currently has a consensus target price of $34.00, indicating a potential upside of 130.35%. Evaxion Biotech A/S has a consensus target price of $18.00, indicating a potential upside of 176.07%. Given Evaxion Biotech A/S's higher probable upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Viridian Therapeutics.

Profitability

This table compares Viridian Therapeutics and Evaxion Biotech A/S's net margins, return on equity and return on assets.

Summary

Evaxion Biotech A/S beats Viridian Therapeutics on 1 of the 1 factors compared between the two stocks.